Acute Myocardial Infarction (AMI)
Conditions
Brief summary
This study is a registry-based cohort investigation, prospectively enrolling patients who were diagnosed with acute myocardial infarction and underwent primary percutaneous coronary intervention (PCI) at Zhongshan Hospital, Fudan University, between January 1, 2009, and December 31, 2028. Baseline clinical characteristics, procedural details, laboratory results, and medication records will be systematically collected and documented. The clinical follow-up will encompass both in-hospital monitoring and post-discharge surveillance extending up to two years after the procedure.
Detailed description
This is a registered prospective study that consecutively enrolled patients who were diagnosed with acute myocardial infarction (AMI) and underwent primary percutaneous coronary intervention (PCI) at Zhongshan Hospital, Fudan University, from January 2009 to December 2028. The study recorded each patient's baseline demographics, clinical history, physical examination data, laboratory results, medication usage, and procedural details. The predefined clinical endpoints include both in-hospital and long-term follow-up events. The former encompasses major adverse cardiovascular and cerebrovascular events (MACCE) composed of all-cause death, recurrent myocardial infarction, ischemia-driven repeat revascularization, malignant arrhythmias, acute heart failure, cardiogenic shock, and cerebrovascular accidents, as well as various bleeding events, gout flares, and intraoperative microcirculatory perfusion status during PCI. The latter includes MACCE composed of all-cause death, recurrent myocardial infarction, ischemia-driven repeat revascularization, readmission for acute heart failure, and cerebrovascular accidents, as well as changes in cardiac function during long-term follow-up. The occurrence of malignant tumors was designated as a falsification endpoint to assess the potential impact of confounding factors.
Interventions
OTHERCollection of baseline characteristics
Collection of baseline clinical characteristics, procedural details, laboratory results, and medication records
Sponsors
Shanghai Zhongshan Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* Elevated or decreasing levels of cardiac troponin T, with at least one measurement exceeding 0.014 ng/mL; * Presence of at least one of the following: symptoms of myocardial ischemia; newly onset ischemic changes on ECG; pathological Q wave; imaging evidence of new loss of viable myocardium or regional wall motion abnormalities consistent with ischemia; coronary angiography confirming the presence of a thrombus; * Undergoing primary PCI; * Voluntary informed consent to participate in the study.
Exclusion criteria
* Inability to complete emergent PCI (e.g., due to intraoperative complications or inability to tolerate the procedure). * Prior administration of thrombolytic therapy before PCI. * Diagnosis of type 2 or type 3 myocardial infarction.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of MACCE during hospitalization | Periprocedural | Major adverse cardiovascular and cerebrovascular events (MACCE) occurring during hospitalization, including all-cause death, recurrent myocardial infarction, ischemia-driven repeat revascularization, malignant arrhythmias, acute heart failure, cardiogenic shock, and cerebrovascular accidents |
| Incidence of MACCE during long-term follow-up | 2 years after PCI | Major adverse cardiovascular and cerebrovascular events (MACCE) occurring during out-of-hospital follow-up, including all-cause death, recurrent acute myocardial infarction, ischemia-driven repeat revascularization, rehospitalization for acute heart failure, and cerebrovascular accident. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of bleeding events during hospitalization | Periprocedural | Various bleeding events during hospitalization |
| Incidence of gout flare during hospitalization | Periprocedural | Gout flare during hospitalization |
| Incidence of myocardial perfusion impairment during primary PCI | Periprocedural | TIMI \< 3 |
Countries
China
Contacts
PRINCIPAL_INVESTIGATORChunfeng Dai, M.D.
Fudan University
Outcome results
None listed